# Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

> **NCT02164864** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 2725 (actual)

## Conditions studied

- Atrial Fibrillation
- Percutaneous Coronary Intervention

## Interventions

- **DRUG:** Dabigatran Etexilate 110mg
- **DRUG:** Warfarin 3mg
- **DRUG:** Aspirin
- **DRUG:** Dabigatran Etexilate 150mg
- **DRUG:** Clopidogrel or Ticagrelor
- **DRUG:** Clopidogrel or Ticagrelor
- **DRUG:** Warfarin 5mg
- **DRUG:** Clopidogrel or Ticagrelor
- **DRUG:** Warfarin 1mg

## Key facts

- **NCT ID:** NCT02164864
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-22
- **Primary completion:** 2017-06-05
- **Final completion:** 2017-06-05
- **Target enrollment:** 2725 (ACTUAL)
- **Last updated:** 2018-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02164864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02164864, "Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02164864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*